Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nerve block may slash opioid use after kidney surgery

NCT ID NCT07704970

Symptom relief Sponsor: Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 15, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This trial tests whether an ultrasound-guided nerve block called QLESP can reduce pain and the need for opioid painkillers after robot-assisted partial nephrectomy for kidney cancer. Adults scheduled for this surgery are randomly assigned to receive either the QLESP block or a standard numbing injection at the surgical wounds. Pain scores and opioid use are tracked for 72 hours after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ropivacaine given as a nerve block (QLESP) or local wound injection
What this could lead to
If it works, this could offer a better way to control pain and reduce reliance on strong opioids after kidney surgery.
What could go wrong
This is a single-center trial with 120 participants, so results may not apply to all hospitals or patients. The nerve block carries small risks like infection or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 to 75 years * Scheduled for elective robot-assisted partial nephrectomy (RAPN) * American Society of Anesthesiologists (ASA) physical status I to III * Body mass index (BMI) 18 to 35 kg/m² * Voluntarily signed informed consent form Able to understand pain scoring and use of patient-controlled analgesia (PCA) Exclusion Criteria: * Language, communication, or comprehension barriers * Infection at the intended puncture site * Coagulopathy or bleeding diathesis * Known allergy or contraindication to local anesthetics or opioids * Use of analgesic medications within the past 3 months * Peripheral neuropathy * Severe cardiac, hepatic, or renal dysfunction * Pregnancy or breastfeeding * Refusal to participate in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nerve block are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney cancer Pain, Postoperative renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nerve block Postoperative pain Renal cell carcinoma (kidney cancer)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.